Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM

View Full Paper
Ask AI
Bookmark
Share

Authors

MKManali KamdarSSScott R. SolomonPJPatrick Johnston

Discussion

Loading...

Member takes

Overview

Randomized trial reports improved Progression-Free Survival in second-line relapsed large B-cell lymphoma, suggesting liso-cel has curative potential.

Key Points

  • This study aims to evaluate the efficacy and safety of liso-cel compared to standard of care in patients with relapsed or refractory large B-cell lymphoma.
  • Randomized, open-label, phase 3 clinical trial comparing liso-cel to standard of care
  • Inclusion of adults with R/R LBCL and eligibility for autologous stem cell transplant
  • Long-term follow-up study analyzing patient outcomes post liso-cel administration
  • Median follow-up in the liso-cel arm was 17.1 months for OS and 16.9 months for PFS in the LTFU study
  • 24-month rates for PFS and OS were 94.7% and 95.1%, respectively
  • No new adverse events were reported during the LTFU study, maintaining a manageable safety profile.

Cite This Study

Kamdar et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df32https://doi.org/10.1182/blood-2025-3710
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study.2024 · 17 citations
  2. 2Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen2024 · 1 citations
  3. 3Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL): First results from CIBMTR.2026
  4. 4Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL2025 · 2 citations
  5. 5Outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with relapsed or refractory (R/R) mantle cell lymphoma (MCL): First real-world data from the CIBMTR.2026